Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer 2008 Mar;50(3):667-70
Date
02/24/2007Pubmed ID
17318876DOI
10.1002/pbc.21171Scopus ID
2-s2.0-38549129707 (requires institutional sign-in at Scopus site) 22 CitationsAbstract
We report a novel regimen for refractory post-transplant T-cell lymphoma (PTL). Our patient presented with non-Epstein-Barr virus (EBV) related, T-cell post-transplant lymphoproliferative disease (PTLD) 3.5 years after liver transplantation. Initially diagnosed as polyclonal PTLD, the disease progressed to a monoclonal, T-cell PTL that was refractory to several chemotherapy regimens but responded to a regimen consisting of fludarabine, cyclophosphamide, cytarabine, and alemtuzumab. Consolidation therapy included high-dose chemotherapy, autologous hematopoietic stem cell rescue, and radiation therapy. She remains in remission 2.5 years later. T-cell PTL is a rare disease with a poor prognosis; this regimen provides a novel, potentially curative approach for its treatment.
Author List
Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJAuthor
Cindy L. Schwartz MD, MPH Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AlemtuzumabAntibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antineoplastic Combined Chemotherapy Protocols
Biliary Atresia
Carboplatin
Carmustine
Cyclophosphamide
Cytarabine
Disease Progression
Doxorubicin
Etoposide
Female
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Transplantation
Humans
Ifosfamide
Immunocompromised Host
Immunosuppressive Agents
Liver Transplantation
Lymphoma, T-Cell, Peripheral
Lymphoproliferative Disorders
Melphalan
Mesna
Postoperative Complications
Prednisone
Radiotherapy, Adjuvant
Transplantation, Autologous
Vidarabine
Vincristine
